N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 5, 2010, Pages 1589-1592

  Mitchell, Michael L ^a   Son, Jong Chan ^b   Guo, Hongyan ^a   Im, Yun A ^b   Cho, Eun Jung ^b   Wang, Jianhong ^a   Hayes, Jaclyn ^a   Wang, Michael ^a   Paul, Amber ^a   Lansdon, Eric B ^a   Chen, James M ^a   Graupe, Doris ^a   Rhodes, Gerry ^a   He, Gong Xin ^a   Geleziunas, Romas ^a   Xu, Lianhong ^a   Kim, Choung U ^a  

^a GILEAD SCIENCES   (United States)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Human immunodeficiency virus; Non nucleoside; Pyrimidinedione; Reverse transcriptase

Indexed keywords

BENZOPHENONE DERIVATIVE; EFAVIRENZ; ETRAVIRINE; POTASSIUM CARBONATE; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHARMACOLOGICAL PARAMETERS;

ANIMALS; ANTI-HIV AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DOGS; HIV REVERSE TRANSCRIPTASE; HUMANS; MICROSOMES; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMINE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 76649109215     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.085     Document Type: Article

References (17)

1. Arendt G., de Nocker D., von Giessen H.J., and Nolting T. Expert Opin. Drug Saf. 6 (2007) 147
2. Fumaz C.R., Muñoz-Moreno J.A., Moltó J., Negredo E., Ferrer M.J., Sirera G., Pérez-Alvarez N., Gómez G., Burger D., and Clotet B. J. Acquir. Immune Defic. Syndr. 38 (2005) 560
3. SUSTIVA® (efavirenz) capsules and tablets: Package insert, Bristol-Myers Squibb Co, Princeton, NJ, USA, 2008. packageinserts.Bms/com/pi/pi_sustiva.pdf.
4. Mitchell M.L., Son J.C., Lee I.Y., Lee C.-K., Kim H.S., Wang J., Hayes J., Wang M., Paul A., Lansdon E.B., Chen J.M., Eisenberg G., Geleziunas R., Xu L., and Kim C.U. Bioorg. Med. Chem. Lett. 20 (2010) 1585
5. Pews R.G., and Puckett W.E. J. Fluorine Chem. 42 (1989) 179
6. Ji L., Chen F.-E., Feng X.-Q., De Clercq E., Balzarini J., and Pannecouque C. Chem. Pharm. Bull. 54 (2006) 1248
7. Danel K., Pedersen E.B., and Nielsen C. Synthesis 9 (1997) 1021
8. Lal G.S., Pez G.P., Pesaresi R.J., Prozonic F.M., and Cheng H. J. Org. Chem. 64 (1999) 7048
9. Coordinates have been deposited into the PDB. For compounds 10b, 10c and 10d, accession codes are 3LAL, 3LAM, and 3LAN, respectively.
10. Hopkins A.L., Ren J., Esnouf R.M., Willcox B.E., Jones Y., Ross C., Miyasaka T., Walker R.T., Tanaka H., Stammers D.K., and Stuart D.I. J. Med. Chem. 39 (1996) 1589 and references cited therein
11. Ren J., and Stammers D.K. Virus Res. 134 (2008) 157
12. Ren J., Chamberlain P.P., Stamp A., Short S.A., Weaver K.L., Romines K.R., Hazen R., Freeman A., Ferris R.G., Andrews C.W., Boone L., Chan J.H., and Stammers D.K. J. Med. Chem. 51 (2008) 5000
13. Das K., Clark Jr. A.D., Lewi P.J., Heeres J., De Jonge M.R., Koymans L.M., Vinkers H.M., Daeyaert F., Ludovici D.W., and Kukla M.J. J. Med. Chem. 47 (2004) 2550
14. Yamaoka Y., Roberts R.D., and Stella V.J. J. Pharm. Sci. 72 (1983) 400
15. Boehme H., and Budde J. Synthesis 11 (1971) 588
16. Krise J.P., Zygmunt J., Georg G.I., and Stella V.J. J. Med. Chem. 42 (1999) 3094
17. In the presence of 50% human serum, compound 10b exhibits a 2.7-fold shift in antiviral potency for wild type and mutant viruses.